
Oncology NEWS International
- Oncology NEWS International Vol 12 No 1
- Volume 12
- Issue 1
NCI Project Targets Cancer Awareness in Asian-American Community
BETHESDA, Maryland-The National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.
BETHESDA, MarylandThe National Cancer Institute (NCI) has launched a 5-year, $7.6 million project at seven leading cancer centers to address the disease among Asian Americans. Although Asian Americans have a relatively low overall risk, their cancer incidence is rising faster than that of any other racial or ethnic group in the United States.
Asian Americans also suffer disproportionately from several forms of the disease, including liver, stomach, and cervical cancer.
The Asian-American community consists of more than 30 distinct ethnic groups and includes about 800 languages and dialects. The Asian-American Network for Cancer Awareness, Research, and Treatment (AANCART) will develop cancer awareness and prevention programs for specific subpopulations. It also aims to increase the number of Asian Americans participating in cancer clinical trials, train more Asian-American health care workers in community cancer prevention, and do research to reduce the cancer burden of this segment of the US population.
The University of California, Davis, Cancer Center will serve as headquarters for the project. Moon S. Chen, Jr., PhD, of UC-Davis, will be the principal investigator.
Other centers participating in the program are the Dana-Farber Cancer Institute, Boston; Herbert Irving Comprehensive Cancer Center, Columbia University, New York; Solove Cancer Research Center, Ohio State University, Columbus; Fred Hutchinson Cancer Research Center, Seattle; University of California, San Francisco, Comprehensive Cancer Center; and the UCLA Jonsson Comprehensive Cancer Center, Los Angeles.
Articles in this issue
almost 23 years ago
Phase II Trial of Phenoxodiol in Recurrent Ovarian Cancer Is launchedalmost 23 years ago
FDA Approves New Taxotere Indication as First-Line Therapy for NSCLCalmost 23 years ago
Most Cancer Pain Is Experienced at the Patient’s Homealmost 23 years ago
HHS Unites Its HIV Advisorsalmost 23 years ago
First NCI Health Disparity Grantsalmost 23 years ago
Pain Therapy Improves Quality of Life for Caregiversalmost 23 years ago
Inex to Seek FDA Approval for Onco TCS (Liposomal Vincristine)almost 23 years ago
CD40L-Expressing Dendritic Cells Eliminate Breast Tumors in Micealmost 23 years ago
Safe Handling Tips for Use of Testosterone Gelalmost 23 years ago
Lumpectomy/Mastectomy Equivalent in Early Breast CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































